Elevance Health (ELV) is back in focus after reporting Q1 revenue and earnings above analyst expectations and lifting full year 2026 adjusted EPS guidance, following higher than expected 2027 Medicare Advantage payment rates.

The recent earnings beat and higher 2026 EPS guidance have coincided with strong momentum, with Elevance Health’s 90 day share price return of 46.46% and a 1 year total shareholder return of 12.87% suggesting sentiment has improved after a softer 3 year total shareholder return, which declined 4.87%.

If Elevance Health’s recent move has you looking beyond large insurers, this could be a good moment to scan the market for other resilient businesses via the 20 top founder-led companies

With Elevance Health now trading close to analyst price targets, yet flagged as a value pick and showing an intrinsic discount of about 60%, the key question is whether there is still an opportunity here or if the market is already pricing in future growth.

Most Popular Narrative: 9.4% Overvalued

The most followed valuation narrative currently puts Elevance Health's fair value at $387.85, which sits below the last close of $424.43, highlighting a gap investors may want to understand.

Strategic investments in digital consumer engagement and Carelon's diversified health services (e.g., pharmacy, care management, behavioral health) are accelerating revenue growth and providing higher-margin, recurring income streams, which should drive both topline and earnings diversity as industry healthcare spending and complexity continue to rise.

Curious what assumptions sit behind that fair value gap, the projected revenue step up, margin rebuild, and the earnings multiple that ties it all together.

Result: Fair Value of $387.85 (OVERVALUED)

However, there is still meaningful policy and cost risk here, particularly if elevated medical utilization persists or if Medicaid and ACA rate adjustments lag underlying claims trends.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Valuation Gap on Earnings

The DCF output points to Elevance Health trading well below an estimated future cash flow value of $1,050.72, which contrasts sharply with the narrative fair value of $387.85 and the current price of $424.43. That gap raises a simple question: is the market too cautious about long term cash generation, or are the DCF inputs too generous?

Next Steps

If the mixed messages in the numbers leave you unsure, that is the point. Now is the time to look through the data yourself and weigh the 4 key rewards.

Looking for more investment ideas?

If Elevance Health sharpened your focus, do not stop here. Use the Simply Wall St screener to hunt for other stocks that fit your style and goals.

• Target stability and consistency by scanning companies with strong financial footing through the solid balance sheet and fundamentals stocks screener (46 results)
• Hunt for potential bargains by filtering companies that combine quality fundamentals with attractive pricing using the 46 high quality undervalued stocks
• Spot early opportunities by tracking smaller companies with resilient metrics inside the 24 elite penny stocks with strong financials

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.